Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.69 |
| ▸ | PPARA | Q07869 | 12/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800156 | 0.92 | PPARG (0.64) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL4393111 | 0.91 | PPARG (0.66) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL3505941 | 0.90 | PPARG (0.58) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL14514345 | 0.89 | KDR (0.78) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL4031039 | 0.87 | KDR (0.74) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL8799608 | 0.86 | PPARG (0.61) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL4744450 | 0.86 | KDR (0.61) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL27650996 | 0.86 | PPARG (0.57) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL9179217 | 0.85 | PPARG (0.60) | PPARGPPARACYP2C9KCNH2KDR | |
| SCHEMBL9176979 | 0.84 | PPARG (0.66) | PPARGPPARACYP2C9KCNH2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | claimed |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY, PATENT DIVISION (US) | 2006-04-20 | — | — | US | claimed |
| EP-1480642-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1480642-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY, PATENT DIVISION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1480642-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885CYP2C9 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.